Welcome to our dedicated page for Amgen SEC filings (Ticker: AMGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Amgen Inc. SEC filings document the regulatory record for a Nasdaq-listed biotechnology company with common stock and registered debt securities. Its 8-K reports cover quarterly and annual earnings releases, Regulation G reconciliations for non-GAAP measures, free cash flow disclosures, material definitive agreements, executive leadership changes and capital markets transactions.
The company's proxy materials describe annual meeting matters, board governance, executive compensation and stockholder voting procedures. Other filings address senior note offerings under registration statements and indentures, Nasdaq listing and registration matters for debt securities, and formal exhibits that define the terms of financing, governance and corporate disclosure events.
Amgen EVP & CFO Peter H. Griffith reported routine equity compensation and related tax withholding. On May 5, 2026, he received 3,640 shares of Common Stock as a grant valued at $0.0000 per share, tied to Restricted Stock Units under Amgen’s Equity Incentive Plan. These RSUs, including 424 Dividend Equivalents, vest in four equal 25% installments starting on May 5, 2027 and will be settled in common shares.
He was also granted 23,752 non-qualified stock options with a $329.59 exercise price, vesting 25% annually from May 5, 2027 and expiring on May 5, 2036. On May 6, 2026, 502 shares of Common Stock were disposed of at $329.59 per share to cover tax obligations. After these transactions, he directly holds 50,706 shares of Amgen common stock.
Amgen SVP & CCO Nancy A. Grygiel reported routine equity compensation activity. She received 485 shares of common stock as a grant, increasing her direct holdings to 7,494 shares, and was granted 3,167 non-qualified stock options at $329.59 per share, vesting in four annual installments starting on May 5, 2027.
The filing also shows 76 shares were withheld at $329.59 per share to cover tax obligations, leaving 7,418 directly held shares afterward. The stock grant consists of Restricted Stock Units that convert one-for-one into common shares as they vest, and the options are exercisable in equal parts through May 5, 2030 with an expiration on May 5, 2036. An indirect 401(k) holding of 106.1864 shares is also reported.
Amgen Inc. senior vice president Rachna Khosla reported routine equity compensation changes. On May 5, 2026, she received an award of 500 shares of common stock at $0.00 per share and a grant of 3,266 non-qualified stock options with a $329.59 exercise price, all under Amgen’s Equity Incentive Plan. The options and related Restricted Stock Units vest in four equal annual installments of 25% each, beginning on May 5, 2027. On May 6, 2026, 79 shares of common stock at $329.59 were withheld to cover tax obligations. After these transactions, she directly holds 8,487 shares of Amgen common stock.
Amgen Inc. senior vice president of human resources Derek Miller reported routine equity compensation activity. He received 910 shares of common stock as a grant, which the footnotes describe as Restricted Stock Units that vest in four equal annual installments of 25% starting on May 5, 2027, and include 116 Dividend Equivalents credited under Amgen’s equity incentive plan.
He was also granted 5,938 non-qualified stock options with an exercise price of $329.59 per share, vesting 25% per year from May 5, 2027 until expiration on May 5, 2036. Separately, 123 shares of common stock were disposed of at $329.59 per share to cover tax obligations, a non-market tax-withholding transaction. After these transactions, Miller directly holds 12,595 Amgen shares.
Amgen Inc. executive David M. Reese reported routine equity compensation awards and a small tax-related share disposition. He received 2,912 shares of Common Stock as a grant on May 5, 2026, including 415 Dividend Equivalents, under Amgen’s Equity Incentive Plan. These Restricted Stock Units vest in four equal annual installments of 25% starting on May 5, 2027, with proration based on completed months of active employment in 2026, and will be settled in common shares on a one-to-one basis. He was also granted 19,002 non-qualified stock options at an exercise price of $329.59 per share, vesting in four equal annual installments of 25% beginning on May 5, 2027 and expiring on May 5, 2036. On May 6, 2026, 454 shares of Common Stock were disposed of at $329.59 per share to cover tax obligations, leaving him with 42,812 Common shares held directly.
Amgen executive Esteban Santos reported routine equity compensation and a small tax-related share disposition. He received 2,730 shares of Amgen common stock on May 5, 2026 as a grant under the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan. These Restricted Stock Units vest in four equal annual installments of 25% each, beginning on May 5, 2027, and will be settled one-for-one in common shares as they vest.
On the same date, he was granted non-qualified stock options covering 17,814 shares of common stock at $329.59 per share, also vesting in four annual 25% installments starting on May 5, 2027 and expiring on May 5, 2036. On May 6, 2026, 427 shares of common stock valued at $329.59 per share were withheld to cover tax obligations, leaving him with 83,369 directly held shares. He also has 909.9906 shares held indirectly through a 401K plan.
ISHRAK OMAR reported acquisition or exercise transactions in this Form 4 filing.
Amgen director Omar Ishrak reported an equity award of 106.1925 shares of Common Stock on a grant/award basis, not an open-market purchase. Following this award, his direct holdings total 6,693.7361 shares of Amgen common stock.
The total includes 418 Dividend Equivalents (DEs) credited under the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan. These DEs are linked to unvested Restricted Stock Units and will be paid out in shares on a one-to-one basis as those units vest.
HOLLEY CHARLES M reported acquisition or exercise transactions in this Form 4 filing.
Amgen Inc. director Charles M. Holley reported updated equity holdings. On May 5, 2026, he received a grant or award of 128.9481 shares of Amgen common stock at no cash cost, increasing his direct ownership to 12,134.0331 shares.
He also reports indirect ownership of 1,260 shares through the Holley Family Trust. The reported holdings include 1,564 Dividend Equivalents credited to his unvested Restricted Stock Units, which are payable in Amgen common stock on a one-for-one basis as those units vest.
Drake Michael V reported acquisition or exercise transactions in this Form 4 filing.
Amgen Inc. director Michael V. Drake received a stock award of 79.6444 shares of common stock on May 5. The grant was recorded at no per-share price, indicating compensation rather than an open-market purchase. After this award, his direct holdings total 5109.2869 shares.
The holdings figure includes 339 Dividend Equivalents granted under Amgen’s Second Amended and Restated 2009 Equity Incentive Plan. These Dividend Equivalents are tied to unvested Restricted Stock Units and will be paid out in common shares on a one-to-one basis as the units vest.
Amgen Inc. executive Esteban Santos, EVP of Operations, reported compensation-related share activity in Common Stock. On May 2, 2026, he had 1,338 shares withheld as a tax-withholding disposition in two F-code transactions at $329.82 per share, a non‑market mechanism used to satisfy tax obligations on equity awards rather than an open-market sale. He also reported 909.9906 shares held indirectly through the Company’s 401(k) Plan, representing interests in Amgen’s stock fund.